Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | SNCA | P37840 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1680771 | 0.96 | CYP2C19 (0.48) | CYP2C19SNCAHIF1ASLC6A3HTT | |
| Bromide SCHEMBL4750734 | 0.96 | CYP2C19 (0.48) | CYP2C19SNCAHIF1ASLC6A3HTT | |
| Bromide SCHEMBL10385733 | 0.79 | CYP2C19 (0.41) | CYP2C19SNCAHIF1ASLC6A3HTT | |
| Bromide SCHEMBL8699689 | 0.74 | TAAR1 (0.48) | CYP2C19HIF1ASLC6A3HTTTAAR1 | |
| Bromide SCHEMBL10385734 | 0.69 | CYP2C19 (0.46) | CYP2C19SLC6A3HTTTAAR1ALDH1A1 | |
| Iodide SCHEMBL159922 | 0.69 | SNCA (0.63) | CYP2C19SNCAHIF1ASLC6A3TAAR1 | |
| Iodide SCHEMBL9321342 | 0.69 | SNCA (0.69) | CYP2C19SNCAHIF1ASLC6A3TAAR1 | |
| Bromide SCHEMBL1839584 | 0.68 | SLC6A4 (0.46) | CYP2C19SNCAHIF1ASLC6A3ALDH1A1 | |
| SCHEMBL7350157 | 0.68 | CYP2C19 (0.75) | CYP2C19ALDH1A1LMNASMN1; SMN2HPGD | |
| Phosphine SCHEMBL28300745 | 0.67 | SNCA (0.61) | CYP2C19SNCAHIF1ASLC6A3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547790-B2 | Optically active 4,4-di-substituted oxazolidine derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20080108828-A1 | Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same | SANKYO COMPANY, LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| EP-1806344-A1 | OPTICALLY ACTIVE 4,4-DISUBSTITUTED OXAZOLIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108828-A1 | Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same | CBR3, C9, COX6C | CYP2C19 68/4885SNCA 4109/4885HIF1A 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.